Stockreport
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,122,652 shares of common stock of the Company at an exercise price of $3.90 per share. The issuance or resale of the shares of common stock issuable upon exercise of the outstanding warrants has been registered pursuant to effective registration statements. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $8.3 million, before deducting financial advisory fees.Roth Capital Partners is acting as the Company’s financial advisor for this transaction.In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exerci
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MBRX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MBRX alerts
MBRX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
NEWS
NEWS
- Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)[GlobeNewswire]
- Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin[GlobeNewswire]
- Moleculin Launches CEO Corner Platform to Share Strategic Insights[GlobeNewswire]
- Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial[GlobeNewswire]
- Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects [Yahoo! Finance][Yahoo! Finance]
- More
MBRX
SEC Filings
SEC Filings
- 2/27/26 - Form PRE
- 2/20/26 - Form 8-K
- 2/18/26 - Form 8-K
- MBRX's page on the SEC website
- More